Detalhe da pesquisa
1.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646664